Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China
Crossref DOI link: https://doi.org/10.1007/s12325-019-01150-x
Published Online: 2019-12-03
Published Print: 2020-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chen, Haotian
Shi, Jihao
Pan, Yipeng
Zhang, Zhou
Fang, Hao
Chen, Ying
Chen, Wendong
Cao, Qian
Funding for this research was provided by:
Xian Janssen
Text and Data Mining valid from 2019-12-03
Version of Record valid from 2019-12-03
Article History
Received: 18 September 2019
First Online: 3 December 2019